The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...

The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...

The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and ...

Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug ...

Addressing obesity through effective weight loss strategies, like those supported by tirzepatide (Zepbound), can ...

Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for ...

Research consistently suggests people with overweight or obesity have more average weight loss on Zepbound than a placebo. The active ingredient in Zepbound is tirzepatide, which falls into a ...

Zepbound (tirzepatide) and Wegovy (semaglutide) both support weight loss by targeting hormones that influence appetite and metabolism. However, their mechanisms differ significantly. Wegovy ...

A new study is shedding light on which of two drugs currently approved by the U.S. Food and Drug Administration for weight loss is most effective at helping people lose more weight in less time.

Treatment with Zepbound, whose generic name is tirzepatide, led to improvements in both sets ... That equates to 45 to 50 ...

Zepbound, Eli Lilly’s weight loss drug, can now be used to treat obstructive sleep apnea in adults with obesity, the FDA said ...